Acquired resistance to antituberculosis drugs in England, wales, and Northern Ireland, 2000–2015

Emerging Infectious Diseases

Volumn 24, Issue 3, 2018, Pages 524-533

  Loutet, Miranda G ^a   Davidson, Jennifer A ^a   Brown, Tim ^a   Dedicoat, Martin ^b   Thomas, H Lucy ^a   Lalor, Maeve K ^a,c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; COHORT ANALYSIS; ENGLAND; EPIDEMIC; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFANT; LUNG DISEASE; MALE; NEWBORN; NONHUMAN; NORTHERN IRELAND; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; WALES; DRUG EFFECT; HISTORY; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; ENGLAND; FEMALE; HISTORY, 21ST CENTURY; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; NORTHERN IRELAND; RETROSPECTIVE STUDIES; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WALES; YOUNG ADULT;

EID: 85042273765     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2403.171362     Document Type: Article

References (37)

1. World Health Organization. Global tuberculosis report 2016 [cited 2016 Dec 2]. http://apps.who.int/iris/bitstre am/10665/250441/1/9789241565394-eng.pdf?ua=1&ua=1
2. World Health Organization. The End TB Strategy [cited 2016 Dec 2]. http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1
3. Public Health England, NHS England. Collaborative TB strategy for England 2015–2020 [cited 2016 Dec 2]. https://www.gov.uk/government/publications/collaborative-tuberculosis-strategy-for-england
4. Public Health England. Reports of cases of tuberculosis to enhanced tuberculosis surveillance systems: UK, 2000 to 2015 [cited 2016 Dec 2]. https://www.gov.uk/government/statistics/reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surveillance-systems
5. Public Health England. Tuberculosis in England: 2016 report (presenting data to the end of 2015) [cited 2016 Dec 2]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/654294/TB_Annual_Report_2016_ GTW2309_errata_v1.2.pdf
6. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329:784–91. http://dx.doi.org/10.1056/NEJM199309093291108
7. Odone A, Calderon R, Becerra MC, Zhang Z, Contreras CC, Yataco R, et al. Acquired and transmitted multidrug resistant tuberculosis: the role of social determinants. PLoS One. 2016;11:e0146642. http://dx.doi.org/10.1371/journal.pone.0146642
8. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis. 2010;14:382–90.
9. Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP. Mortality among tuberculosis patients with acquired resistance to second-line antituberculosis drugs—United States, 1993–2008. Clin Infect Dis. 2014;59:465–72. http://dx.doi.org/10.1093/cid/ciu372
10. Monedero I, Caminero JA. Management of multidrug-resistant tuberculosis: an update. Ther Adv Respir Dis. 2010;4:117–27. http://dx.doi.org/10.1177/1753465810365884
11. Perri BR, Proops D, Moonan PK, Munsiff SS, Kreiswirth BN, Goranson C, et al. Mycobacterium tuberculosis cluster with developing drug resistance, New York, New York, USA, 2003– 2009. Emerg Infect Dis. 2011;17:372–8. http://dx.doi.org/10.3201/eid1703.101002
12. Cox HS, Niemann S, Ismailov G, Doshetov D, Orozco JD, Blok L, et al. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin Infect Dis. 2007;44:1421–7. http://dx.doi.org/10.1086/517536
13. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update [cited 2017 Feb 1]. http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583_eng.pdf.
14. World Health Organization. Treatment of tuberculosis guidelines: fourth edition [cited 2017 Feb 1]. http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1
15. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update [cited 2017 Nov 15]. http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf
16. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit–variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol. 2006;44:4498–510. http://dx.doi.org/10.1128/JCM.01392-06
17. Health Protection Agency. Mycobacterium tuberculosis strain typing: a guide to data production and distribution [cited 2017 Feb 1]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/433731/HPA_VNTR_280812_final.pdf
18. Nikolayevskyy V, Hillemann D, Richter E, Ahmed N, van der Werf MJ, Kodmon C, et al.; ERLTB-Net Network. External quality assessment for tuberculosis diagnosis and drug resistance in the European Union: a five year multicentre implementation study. PLoS One. 2016;11:e0152926. http://dx.doi.org/10.1371/journal.pone.0152926
19. Aldridge RW, Shaji K, Hayward AC, Abubakar I. Accuracy of probabilistic linkage using the enhanced matching system for public health and epidemiological studies. PLoS One. 2015; 10:e0136179. http://dx.doi.org/10.1371/journal.pone.0136179
20. Gao J, Ma Y, Du J, Zhu G, Tan S, Fu Y, et al. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with standard short-course chemotherapy for tuberculosis. BMC Pulm Med. 2016 Feb 4 [cited 2016 Dec 2]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743330/
21. Mathuria JP, Samaria JK, Srivastava GN, Mathuria BL, Ojha SK, Anupurba S. Primary and acquired drug resistance patterns of Mycobacterium tuberculosis isolates in India: a multicenter study. J Infect Public Health. 2013;6:456–64. http://dx.doi.org/10.1016/j.jiph.2013.03.003
22. Smith C, Abubakar I, Thomas HL, Anderson L, Lipman M, Reacher M. Incidence and risk factors for drug intolerance and association with incomplete treatment for tuberculosis: analysis of national case registers for England, Wales and Northern Ireland, 2001–2010. Thorax. 2014;69:956–8. http://dx.doi.org/10.1136/thoraxjnl-2013-204503
23. Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, et al.; Global Preserving Effective TB Treatment Study (PETTS) Investigators. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59:1049–63. http://dx.doi.org/10.1093/cid/ciu572
24. Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP. Acquired resistance to second-line drugs among persons with tuberculosis in the United States. Clin Infect Dis. 2012;55:1600–7. http://dx.doi.org/10.1093/cid/cis748
25. Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty [cited 2017 Apr 20]. http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC5240443/
26. Arnold A, Cooke GS, Kon OM, Dedicoat M, Lipman M, Loyse A, et al. Drug resistant TB: UK multicentre study (DRUMS): treatment, management and outcomes in London and West Midlands 2008–2014. J Infect. 2017;74:260–71. http://dx.doi.org/10.1016/j.jinf.2016.12.005
27. Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho S-N, et al.; Global PETTS Investigators. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012;380:1406–17. http://dx.doi.org/10.1016/S0140-6736(12)60734-X
28. Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee H, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008;46:42–9. http://dx.doi.org/10.1086/524017
29. Andrews JR, Shah NS, Weissman D, Moll AP, Friedland G, Gandhi NR. Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. PLoS ONE. 2010 Dec 29 [cited 2017 Apr 20]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012092/
30. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis. 2007;7:328–37. http://dx.doi.org/10.1016/S1473-3099(07)70108-1
31. Brown T, Nikolayevskyy V, Velji P, Drobniewski F. Associations between Mycobacterium tuberculosis strains and phenotypes. Emerg Infect Dis. 2010;16:272–80. http://dx.doi.org/10.3201/eid1602.091032
32. Yuen CM, Kurbatova EV, Click ES. Association between Mycobacterium tuberculosis complex phylogenetic lineage and acquired drug resistance. PLoS One. 2013;8:e83006.
33. Smith S, Ershova J, Vlasova N, Nikishova E, Tarasova I, Eliseev P, et al. Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005–2010. Emerg Infect Dis [cited 2016 Dec 2]. http://wwwnc.cdc.gov/eid/article/21/6/14-1907_article
34. Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, et al.; Global PETTS Investigators. Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin Infect Dis. 2016;62:418–30.
35. Kempker RR, Kipiani M, Mirtskhulava V, Tukvadze N, Magee MJ, Blumberg HM. Acquired drug resistance in Mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis. Emerg Infect Dis. 2015;21:992–1001. http://dx.doi.org/10.3201/eid2106.141873
36. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, et al.; Modernizing Medical Microbiology (MMM) Informatics Group. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015;15:1193–202. http://dx.doi.org/10.1016/S1473-3099(15)00062-6
37. Aung KJM, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014;18:1180–7. http://dx.doi.org/10.5588/ijtld.14.0100